Search research articles
Contact Us
Filters
Showing results (81-90 of 235) with videos related to
Page
of 24
Sort By:
Cancer
|
November 20, 2009
Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign
Matthias R Benz, Johannes Czernin, Sarah M Dry, et al.
Cancer
|
October 25, 2011
3'-deoxy-3'-[18F]fluorothymidine positron emission tomography for response assessment in soft tissue sarcoma: a pilot study to correlate imaging findings with tissue thymidine kinase 1 and Ki-67 activity and histopathologic response
Matthias R Benz, Johannes Czernin, Martin S Allen-Auerbach, et al.
The American Journal of Surgical Pathology
|
January 7, 2016
Recurrent CIC Gene Abnormalities in Angiosarcomas: A Molecular Study of 120 Cases With Concurrent Investigation of PLCG1, KDR, MYC, and FLT4 Gene Alterations
Shih-Chiang Huang, Lei Zhang, Yun-Shao Sung, et al.
Journal of Clinical Pharmacology
|
October 12, 2020
Population Pharmacokinetic Analysis of Pexidartinib in Healthy Subjects and Patients With Tenosynovial Giant Cell Tumor or Other Solid Tumors
Ophelia Yin, Andrew J Wagner, Jia Kang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 26, 2021
Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial
Robin L Jones, Andrew J Wagner, Akira Kawai, et al.
Investigational New Drugs
|
March 9, 2021
A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors
Analia Azaro, Christophe Massard, William D Tap, et al.
Journal of Oncology Practice
|
July 4, 2019
Incidence and Management of Olaratumab Infusion-Related Reactions
Brian A Van Tine, Rangaswamy Govindarajan, Steven Attia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 18, 2025
Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma
William D Tap, Gregory M Cote, Howard Burris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 9, 2023
Bolus versus Continuous Intravenous Delivery of Doxorubicin in Soft-Tissue Sarcomas: Post Hoc Analysis of a Prospective Randomized Trial (SARC021/TH CR-406)
Lee D Cranmer, Yao Lu, Rachel S Heise, et al.
Journal of Adolescent and Young Adult Oncology
|
July 15, 2024
Harmonization of the Upfront Osteosarcoma Treatment Paradigm for Adolescents and Young Adults
Nicole P Daukshus, Viswatej Avutu, Emily Long Sarro, et al.
Page
of 24
Search research articles
Search
Showing results (81-90 of 235) with videos related to
Sort By:
Page
of 24
Cancer
|
November 20, 2009
Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign
Matthias R Benz, Johannes Czernin, Sarah M Dry, et al.
Cancer
|
October 25, 2011
3'-deoxy-3'-[18F]fluorothymidine positron emission tomography for response assessment in soft tissue sarcoma: a pilot study to correlate imaging findings with tissue thymidine kinase 1 and Ki-67 activity and histopathologic response
Matthias R Benz, Johannes Czernin, Martin S Allen-Auerbach, et al.
The American Journal of Surgical Pathology
|
January 7, 2016
Recurrent CIC Gene Abnormalities in Angiosarcomas: A Molecular Study of 120 Cases With Concurrent Investigation of PLCG1, KDR, MYC, and FLT4 Gene Alterations
Shih-Chiang Huang, Lei Zhang, Yun-Shao Sung, et al.
Journal of Clinical Pharmacology
|
October 12, 2020
Population Pharmacokinetic Analysis of Pexidartinib in Healthy Subjects and Patients With Tenosynovial Giant Cell Tumor or Other Solid Tumors
Ophelia Yin, Andrew J Wagner, Jia Kang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 26, 2021
Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial
Robin L Jones, Andrew J Wagner, Akira Kawai, et al.
Investigational New Drugs
|
March 9, 2021
A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors
Analia Azaro, Christophe Massard, William D Tap, et al.
Journal of Oncology Practice
|
July 4, 2019
Incidence and Management of Olaratumab Infusion-Related Reactions
Brian A Van Tine, Rangaswamy Govindarajan, Steven Attia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 18, 2025
Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma
William D Tap, Gregory M Cote, Howard Burris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 9, 2023
Bolus versus Continuous Intravenous Delivery of Doxorubicin in Soft-Tissue Sarcomas: Post Hoc Analysis of a Prospective Randomized Trial (SARC021/TH CR-406)
Lee D Cranmer, Yao Lu, Rachel S Heise, et al.
Journal of Adolescent and Young Adult Oncology
|
July 15, 2024
Harmonization of the Upfront Osteosarcoma Treatment Paradigm for Adolescents and Young Adults
Nicole P Daukshus, Viswatej Avutu, Emily Long Sarro, et al.
Page
of 24